2-苯基-4-羟甲基噻唑 | 23780-13-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-苯基-4-羟甲基噻唑
• 英文名称: (2-phenylthiazol-4-yl)methanol
• 英文别名: 2-phenyl-4-hydroxymethylthiazole；4-hydroxymethyl-2-phenylthiazole；2-Phenyl-4-hydroxymethyl-thiazol；4-Hydroxymethyl-2-phenyl-thiazol；(2-phenyl-1,3-thiazol-4-yl)methanol
• CAS: 23780-13-4
• 化学式: C₁₀H₉NOS
• 分子量: 191.254
• InChiKey: HNFDKPSDOQRBBX-UHFFFAOYSA-N

物化性质

• 熔点：
  65 °C
• 沸点：
  372.2±34.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R24/25
• 海关编码：
  2934100090
• 安全说明：
  S22,S36/37/39
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352,P304+P340+P312,P305+P351+P338+P310,P332+P313,P362,P403+P233,P405,P501
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H315,H318,H335

SDS

Name:	(2-Phenyl-1 3-thiazol-4-yl)methanol 97% Material Safety Data Sheet
Synonym:	2-Phenyl-hydroxymethyl thiazol
CAS:	23780-13-4

Section 1 - Chemical Product MSDS Name:(2-Phenyl-1 3-thiazol-4-yl)methanol 97% Material Safety Data Sheet
Synonym:2-Phenyl-hydroxymethyl thiazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
23780-13-4	(2-Phenyl-1,3-thiazol-4-yl)methanol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: 24/25

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Toxic in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 23780-13-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 67 - 70 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9NOS
Molecular Weight: 191

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 23780-13-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(2-Phenyl-1,3-thiazol-4-yl)methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
R 24/25 Toxic in contact with skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 23780-13-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 23780-13-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 23780-13-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯基-4-羟甲基噻唑 在 2-碘酰基苯甲酸 作用下， 以 二甲基亚砜 为溶剂， 反应 0.08h， 生成 1-((2-phenylthiazol-4-yl)methylene)thiosemicarbazide
  参考文献：
  名称：

  微波辅助无溶剂合成一些新型噻唑取代缩氨基硫脲类似物：抗菌和抗癌研究

  摘要：

  对抗生素耐药性的增加迫使研究人员设计针对多重耐药病原微生物的新型活性化合物。通过氨基硫脲与2-芳基-4-甲酰基噻唑、2-芳基-5-甲酰基-4-甲基噻唑和/或5-乙酰基-2-芳基-4-甲基噻唑化合物反应合成了一系列缩氨基硫脲衍生物。评估了这些基于缩氨基硫脲的噻唑加合物对结核病 H37Ra 和牛 BCG 分枝杆菌的抑制活性。他们针对两种癌细胞系评估了它们的细胞毒性：结肠癌（HCT-116）和宫颈癌（HeLa）。值得注意的是，即使在最高浓度下，这些缩氨基硫脲对这些细胞系也表现出最小的细胞毒性作用。此外，所制备的缩氨基硫脲衍生物对枯草芽孢杆菌和金黄色葡萄球菌（革兰氏阳性细菌病原体）以及大肠杆菌和荧光假单胞菌（革兰氏阴性细菌病原体）具有显着的抗菌功效。虽然大多数制备的缩氨基硫脲衍生物对白色念珠菌（一种真菌菌株）表现出中等活性，但其性能值得注意。缩氨基硫脲基噻唑加合物也采用无溶剂方法在微波辐射下成功合

  DOI：

  10.1002/bio.4587
• 作为产物：
  描述：

  硫代苯甲酰胺 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 反应 4.5h， 生成 2-苯基-4-羟甲基噻唑
  参考文献：
  名称：

  新型噻唑类游离脂肪酸受体1激动剂用于2型糖尿病的设计，合成及构效关系研究

  摘要：

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。

  DOI：

  10.1016/j.ejmech.2016.02.040

文献信息

• Single-Step Microwave-Mediated Synthesis of Oxazoles and Thiazoles from 3-Oxetanone: A Synthetic and Computational Study
  作者：David Orr、Alexandra Tolfrey、Jonathan M. Percy、Joanna Frieman、Zoë A. Harrison、Matthew Campbell-Crawford、Vipulkumar K. Patel

  DOI：10.1002/chem.201301011

  日期：2013.7.15

  The direct microwave‐mediated condensation between 3‐oxetanone and primary amides and thioamides has delivered moderate to good yields of (hydroxymethyl)oxazoles and (hydroxymethyl)thiazoles. The reactions use a sustainable solvent and only require short reaction times. These are highly competitive methods for the construction of two classes of valuable heteroarenes, which bear a useful locus for further

  3-氧杂环丁酮与伯酰胺和硫代酰胺之间的直接微波介导缩合反应产生了中等到良好的（羟甲基）恶唑和（羟甲基）噻唑收率。反应使用可持续的溶剂，只需要很短的反应时间。这些是构建两类有价值的杂芳烃的高度竞争性方法，它们具有进一步阐明的有用位置。电子结构计算表明，事件的顺序涉及sp 3处硫属元素原子的攻击碳和烷基-氧裂解。清楚地表明了酸催化的关键作用，并证明了酸强度的重要性。计算的势垒也与所观察到的硫酰胺和酰胺反应性顺序完全一致。自发的开环涉及适度的CO裂解，减缓了应力释放的程度。在酸催化的途径上，CO的裂解仍然不太广泛，但是通过羧酸催化剂，质子转移到核反应堆中的进展非常快，而基本上是用甲磺酸完成的。
• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION<br/>[FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013163279A1

  公开（公告）日：2013-10-31

  The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• PAR4 AGONIST PEPTIDES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130289238A1

  公开（公告）日：2013-10-31

  The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

  本发明提供PAR4激动肽。这些肽对于开发强大的PAR4受体测定方法非常有用。
• Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells
  作者：Xin Dang、Shuwen Lei、Shuhua Luo、Yixin Hu、Juntao Wang、Dongdong Zhang、Dan Lu、Faqin Jiang、Lei Fu

  DOI：10.1016/j.bioorg.2021.105015

  日期：2021.9

  production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

  线粒体是细胞维持必要代谢活动的关键能量生产来源。针对功能失调的线粒体特征一直是线粒体相关疾病研究的热点。对癌性线粒体代谢的研究是肿瘤治疗中持续关注的问题。在此，我们基于我们早期对线粒体靶向剂的研究，着手评估新型 TPP-噻唑衍生物家族的抗癌活性。具体而言，我们设计并合成了一系列 TPP-噻唑衍生物，并通过 MTT 测定显示大多数合成的化合物有效抑制了三种癌细胞系（HeLa、PC3 和 MCF-7）。在结构修改后，我们探索了 SAR 关系并确定了最有希望的化合物R13（IC50 of 5.52 μM) 用于进一步研究。同时，我们进行了 ATP 产生测定以评估所选化合物对 HeLa 细胞能量产生的抑制作用。结果显示测试化合物显着抑制癌细胞的ATP产生。总体而言，我们设计并合成了一系列对癌细胞具有显着细胞毒性并有效抑制线粒体能量产生的化合物。